Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Delivery of therapeutic proteins.

Literature DB >> 20049941

Delivery of therapeutic proteins.

Dipak S Pisal¹, Matthew P Kosloski, Sathy V Balu-Iyer.

Abstract

The safety and efficacy of protein therapeutics are limited by three interrelated pharmaceutical issues, in vitro and in vivo instability, immunogenicity and shorter half-lives. Novel drug modifications for overcoming these issues are under investigation and include covalent attachment of poly(ethylene glycol) (PEG), polysialic acid, or glycolic acid, as well as developing new formulations containing nanoparticulate or colloidal systems (e.g., liposomes, polymeric microspheres, polymeric nanoparticles). Such strategies have the potential to develop as next generation protein therapeutics. This review includes a general discussion on these delivery approaches. (c) 2010 Wiley-Liss, Inc. and the American Pharmacists Association

Entities: Chemical Disease Gene Mutation Species

Mesh：

Substances：

Year: 2010 PMID： 20049941 PMCID： PMC2857543 DOI： 10.1002/jps.22054

Source DB: PubMed Journal: J Pharm Sci ISSN： 0022-3549 Impact factor: 3.534

145 in total

Review 1. Polymeric delivery of proteins and plasmid DNA for tissue engineering and gene therapy.

Authors: T P Richardson; W L Murphy; D J Mooney
Journal: Crit Rev Eukaryot Gene Expr Date: 2001 Impact factor: 1.807

Review 2. Nanostructured lipid carrier-based hydrogel formulations for drug delivery: a comprehensive review.

Authors: Slavomira Doktorovova; Eliana B Souto
Journal: Expert Opin Drug Deliv Date: 2009-02 Impact factor: 6.648

3. Effect of the spraying conditions and nozzle design on the shape and size distribution of particles obtained with supercritical fluid drying.

Authors: Andréanne Bouchard; Natasa Jovanović; Anne H de Boer; Angel Martín; Wim Jiskoot; Daan J A Crommelin; Gerard W Hofland; Geert-Jan Witkamp
Journal: Eur J Pharm Biopharm Date: 2008-04-11 Impact factor: 5.571

4. Relationship of effective molecular size to systemic clearance in rats of recombinant interleukin-2 chemically modified with water-soluble polymers.

Authors: M J Knauf; D P Bell; P Hirtzer; Z P Luo; J D Young; N V Katre
Journal: J Biol Chem Date: 1988-10-15 Impact factor: 5.157

5. Inhibition of liver metastasis by targeting of immunomodulators using mannosylated liposome carriers.

Authors: Praneet Opanasopit; Megumi Sakai; Makiya Nishikawa; Shigeru Kawakami; Fumiyoshi Yamashita; Mitsuru Hashida
Journal: J Control Release Date: 2002-04-23 Impact factor: 9.776

6. Protein-liposome conjugates using cysteine-lipids and native chemical ligation.

Authors: Sanne W A Reulen; Wilco W T Brusselaars; Sander Langereis; Willem J M Mulder; Monica Breurken; Maarten Merkx
Journal: Bioconjug Chem Date: 2007-02-22 Impact factor: 4.774

7. PEG-ADA replacement therapy for adenosine deaminase deficiency: an update after 8.5 years.

Authors: M S Hershfield
Journal: Clin Immunol Immunopathol Date: 1995-09

8. Enhanced circulation half-life of site-specific PEGylated rhG-CSF: optimization of PEG molecular weight.

Authors: Yanqin Zhai; Yongjiang Zhao; Jiandu Lei; Zhiguo Su; Guanghui Ma
Journal: J Biotechnol Date: 2009-06-02 Impact factor: 3.307

9. Attachment of degradable poly(ethylene glycol) to proteins has the potential to increase therapeutic efficacy.

Authors: M J Roberts; J M Harris
Journal: J Pharm Sci Date: 1998-11 Impact factor: 3.534

10. Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase.

Authors: Nancy J Ganson; Susan J Kelly; Edna Scarlett; John S Sundy; Michael S Hershfield
Journal: Arthritis Res Ther Date: 2006 Impact factor: 5.156

110 in total

Review 1. Nanoparticles for retinal gene therapy.

Authors: Shannon M Conley; Muna I Naash
Journal: Prog Retin Eye Res Date: 2010-05-07 Impact factor: 21.198

Review 2. Clinical developments in nanotechnology for cancer therapy.

Authors: Jeremy D Heidel; Mark E Davis
Journal: Pharm Res Date: 2010-06-12 Impact factor: 4.200

Review 3. Clinical development of a novel CD1d-binding NKT cell ligand as a vaccine adjuvant.

Authors: Neal N Padte; Xiangming Li; Moriya Tsuji; Sandhya Vasan
Journal: Clin Immunol Date: 2010-12-24 Impact factor: 3.969

Review 4. Extended release formulations using silk proteins for controlled delivery of therapeutics.

Authors: Burcin Yavuz; Laura Chambre; David L Kaplan
Journal: Expert Opin Drug Deliv Date: 2019-07-01 Impact factor: 6.648

Review 5. Novel Therapy to Treat Corneal Epithelial Defects: A Hypothesis with Growth Hormone.

Authors: Barbara Wirostko; MaryJane Rafii; David A Sullivan; Julia Morelli; Juan Ding
Journal: Ocul Surf Date: 2015-03-28 Impact factor: 5.033

Review 6. Strategic approaches to optimizing peptide ADME properties.

Authors: Li Di
Journal: AAPS J Date: 2014-11-04 Impact factor: 4.009

7. A Population Pharmacokinetic-Pharmacodynamic Model of Pegfilgrastim.

Authors: Ari Brekkan; Luis Lopez-Lazaro; Gunnar Yngman; Elodie L Plan; Chayan Acharya; Andrew C Hooker; Suresh Kankanwadi; Mats O Karlsson
Journal: AAPS J Date: 2018-08-15 Impact factor: 4.009

Review 8. Nanoscale platforms for messenger RNA delivery.

Authors: Bin Li; Xinfu Zhang; Yizhou Dong
Journal: Wiley Interdiscip Rev Nanomed Nanobiotechnol Date: 2018-05-04

Review 9. Polysaccharide-Based Controlled Release Systems for Therapeutics Delivery and Tissue Engineering: From Bench to Bedside.

Authors: Tianxin Miao; Junqing Wang; Yun Zeng; Gang Liu; Xiaoyuan Chen
Journal: Adv Sci (Weinh) Date: 2018-01-08 Impact factor: 16.806

10. A cell-penetrating peptide suppresses the hypoxia inducible factor-1 function by binding to the helix-loop-helix domain of the aryl hydrocarbon receptor nuclear translocator.

Authors: Yu Wang; John D Thompson; William K Chan
Journal: Chem Biol Interact Date: 2013-02-27 Impact factor: 5.192